MedPath

Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage

Not Applicable
Not yet recruiting
Conditions
Intracranial Hemorrhages
Interventions
Procedure: Sham remote ischemic conditioning
Procedure: Remote ischemic conditioning
Registration Number
NCT03484936
Lead Sponsor
Yi Yang
Brief Summary

The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

Detailed Description

Intracerebral hemorrhage is a devastating disease with a high rate of severe disability and death, while no specific treatment has been proven to improve functional outcome. As a result, new approaches need to be developed to treat intracerebral hemorrhage. Animal and human trials showed treatment with remote ischemic conditioning was safe for intracerebral hemorrhage. And repetitive remote ischemic conditioning has been shown to improve sensorimotor and neuropathological outcomes following experimental hemorrhagic stroke. Therefore, we hypothesize that repetitive remote ischemic conditioning could improve functional outcome in patients with intracerebral hemorrhage. We design this prospective, multicenter, randomized controlled double-blind trial to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
530
Inclusion Criteria
  1. Age ≥ 18 years
  2. Supratentorial intracerebral hemorrhage confirmed by brain CT scan
  3. Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1
  4. NIHSS score ≥ 4 and GCS ≥ 6 upon presentation
  5. Able to commence RIC treatment within 12 hours of stroke onset
  6. Signed and dated informed consent is obtained.
Exclusion Criteria
  1. Definite evidence of secondary ICH, such as structural abnormality, brain tumor, thrombolytic drug, and other causes
  2. A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria
  3. Already booked for surgical treatment
  4. Life expectancy of less than 90 days due to comorbid conditions
  5. Severe hematologic disease
  6. Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban.
  7. Concurrent use of glibenclamide or nicorandil
  8. Any soft tissue, orthopedic, or vascular injury, wounds or fractures in healthy upper limb which may pose a contraindication for application of RIC
  9. Severe hepatic and renal dysfunction
  10. Platelet count <100×10^9/L
  11. Coagulopathy defined as INR,APTT,and PT beyond the upper limit of normal range
  12. Known pregnancy, or positive pregnancy test, or breastfeeding
  13. Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial
  14. A high likelihood that the patient will not adhere to the study treatment and follow up regimen
  15. Patients unsuitable for enrollment in the clinical trial according to investigators decision making.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham RIC+Standard medical treatmentSham remote ischemic conditioningSham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
RIC+Standard medical treatmentRemote ischemic conditioningRemote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
Primary Outcome Measures
NameTimeMethod
Proportion of patients with Modified Rankin Scale (mRS) Score 0-23 months

The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.

Secondary Outcome Measures
NameTimeMethod
Frequency of adverse events3 months

The safety endpoints will include all adverse events until day-7 or discharge (whichever is earlier), and severe adverse events through day-90 after the onset of intracerebral hemorrhage.

Trial Locations

Locations (1)

First Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

© Copyright 2025. All Rights Reserved by MedPath